文献速递新生儿儿童神经与发育行为

早产儿呼吸暂停新生儿枸橼酸咖啡因治疗11年后的学业、运动功能与行为:CAP随机临床试验11年随访

Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2017-01-01

该研究对CAP随机对照试验中出生体重500-1250g的早产儿进行11年随访,共920名儿童有主要结局数据。结果显示,新生儿枸橼酸咖啡因治疗未显著降低学业、运动和行为功能损害的综合发生率,但与运动损害风险降低相关。

要点

  • 咖啡因组与安慰剂组功能损害综合发生率分别为31.7%和37.6%,差异无统计学意义。
  • 咖啡因治疗与11岁时运动损害风险降低相关(19.7% vs 27.5%,调整OR 0.66)。
  • 学业不良和行为问题发生率在两组间 broadly similar,无显著差异。

核心结论

  • 早产儿呼吸暂停的枸橼酸咖啡因治疗未显著降低11岁时学业、运动和行为损害的综合发生率。
  • 咖啡因治疗与11岁时运动损害风险降低相关。
  • 在本试验所用剂量下,新生儿咖啡因治疗至中学年龄仍有效且安全。

研究设计与样本

  • 研究为CAP随机安慰剂对照试验的11年随访研究,在加拿大、澳大利亚和英国的14家学术医院进行。
  • 纳入1999年10月11日至2004年10月22日期间入组CAP试验的出生体重500-1250g儿童,共1202名 eligible,920名(76.5%)有主要结局充分数据。
  • 干预为枸橼酸咖啡因或安慰剂,直至不再需要呼吸暂停药物治疗。

关键数值与推荐

  • 功能损害综合结局定义为学业不良、运动损害和行为问题中至少一项。
  • 学业不良定义为Wide Range Achievement Test-4中至少1个标准分低于均值超过2个标准差。
  • 运动损害定义为Movement Assessment Battery for Children-Second Edition百分位≤5。
  • 行为问题定义为Child Behavior Checklist总问题T分高于均值至少2个标准差。

临床怎么用

  • 对于出生体重500-1250g的早产儿,新生儿枸橼酸咖啡因治疗至中学年龄未见安全信号。
  • 咖啡因治疗可能降低11岁时运动损害风险,但未显著改善综合功能结局。
  • 临床决策应权衡咖啡因治疗对呼吸暂停的获益与长期功能结局,本试验剂量下长期安全性良好。

局限性

  • 主要结局数据完整率为76.5%(920/1202),存在失访偏倚可能。
  • 研究仅在加拿大、澳大利亚和英国进行,结果外推需谨慎。
  • 部分分析纳入最多24名瑞典试验参与者,数据来源不完全一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Caffeine citrate therapy for apnea of prematurity reduces the rates of bronchopulmonary dysplasia, severe retinopathy, and neurodevelopmental disability at 18 months and may improve motor function at 5 years. OBJECTIVE: To evaluate whether neonatal caffeine therapy is associated with improved functional outcomes 11 years later. DESIGN, SETTING, AND PARTICIPANTS: A follow-up study was conducted at 14 academic hospitals in Canada, Australia, and the United Kingdom from May 7, 2011, to May 27, 2016, of English- or French-speaking children who had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between October 11, 1999, and October 22, 2004. A total of 1202 children with birth weights of 500 to 1250 g were eligible for this study; 920 (76.5%) had adequate data for the main outcome. INTERVENTIONS: Caffeine citrate or placebo until drug therapy for apnea of prematurity was no longer needed. MAIN OUTCOMES AND MEASURES: Functional impairment was a composite of poor academic performance (defined as at least 1 standard score greater than 2 SD below the mean on the Wide Range Achievement Test-4), motor impairment (defined as a percentile rank of ≤5 on the Movement Assessment Battery for Children-Second Edition), and behavior problems (defined as a Total Problem T score ≥2 SD above the mean on the Child Behavior Checklist). RESULTS: Among the 920 children (444 females and 476 males; median age, 11.4 years [interquartile range, 11.1-11.8 years]), the combined rates of functional impairment were not significantly different between the 457 children assigned to receive caffeine compared with the 463 children assigned to receive placebo (145 [31.7%] vs 174 [37.6%]; adjusted odds ratio, 0.78; 95% CI, 0.59-1.02; P = .07). With all available data, including those from up to 24 Swedish trial participants, the rates of poor academic performance on 1 or more of 4 subtests (66 of 458 [14.4%] vs 61 of 462 [13.2%]; adjusted odds ratio, 1.11; 95% CI, 0.77-1.61; P = .58) and behavior problems (52 of 476 [10.9%] vs 40 of 481 [8.3%]; adjusted odds ratio, 1.32; 95% CI, 0.85-2.07; P = .22) were broadly similar between the group that received caffeine and the group that received placebo. However, caffeine therapy was associated with a reduced risk of motor impairment compared with placebo (90 of 457 [19.7%] vs 130 of 473 [27.5%]; adjusted odds ratio, 0.66; 95% CI, 0.48-0.90; P = .009). CONCLUSIONS AND RELEVANCE: Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight. At the doses used in this trial, neonatal caffeine therapy is effective and safe into middle school age. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00182312; isrctn.org Identifier: ISRCTN44364365.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Schmidt B, Roberts RS, Anderson PJ, et al. Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. JAMA Pediatr. 2017. PMID: 28437520. doi:10.1001/jamapediatrics.2017.0238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。